A case report of delayed diagnosis of danon disease
Caused by a newly recognized mutation in the lysosome-associated membrane protein-2 gene

Ying Zhang, MBBS, Hang Ren, MBBS, Shanshan Zhou, PhD

Abstract

Introduction: Danon disease is a rare X-linked dominant genetic disorder caused by defects in the lysosome-associated membrane protein 2 (LAMP2) gene. Unless treated, cardiogenic death is the main cause of mortality. This case report describes a 19-year-old man who was diagnosed with Danon disease and survived for 3 years from symptom onset to death. The mutation in his LAMP2 gene (p.Gly221Ilefs*19) had not been previously reported.

Patient concerns: A 19-year-old man patient was hospitalized for intermittent palpitations. He had no family history of cardiomyopathy, arrhythmia, or sudden cardiac death, but his sister had died of cirrhosis at age 12 years, but the exact cause of cirrhosis was unknown.

Diagnosis: Exome sequencing and Sanger sequencing identified a novel missense mutation (p.Gly221Ilefs*19) in the LAMP2 gene of the proband. This mutation was also detected in his mother, confirming the diagnosis of Danon disease.

Interventions: The patient experienced various types of arrhythmia throughout the clinical process, including Wolff-Parkinson-White syndrome, non-sustained atrial tachycardia, atrial flutter, and third-degree atrioventricular block. He was therefore treated with cardiac ablation procedures and cardiac resynchronization therapy.

Outcomes: The period from the onset of symptoms to the onset of heart failure was 2 years. The patient died of cardiogenic death during the third year, at age 22 years.

Lessons: Danon disease is a rare disease that is difficult to recognize because of its hidden early manifestations. Early identification of its clinical symptoms can lead to early diagnosis and treatment.

Abbreviations: AL = monoclonal immunoglobulin light-chain, AVB = atrioventricular block, CMRI = cardiovascular magnetic resonance imaging, ECG = electrocardiogram, HCM = hypertrophic cardiomyopathy, ICD = implantable cardioverter defibrillator, LAMP2 = lysosome-associated membrane protein 2, LGE = late gadolinium enhancement, TTR = transthyretin, WPW = Wolff-Parkinson-White.

Keywords: cardiomyopathy, danon disease, lysosome-associated membrane protein 2, sudden cardiac death

1. Introduction

Danon disease is a metabolic disorder first described in a report on 2 boys with cardiomyopathy, skeletal myopathy, and intellectual disability.[1] This rare X-linked dominant genetic disorder was found to be caused by defects in the lysosome-associated membrane protein 2 (LAMP2) gene. Because of its X-linked inheritance, males are affected both earlier and more severely than females.[2] Many reports have substantiated the clinical triad of Danon disease, consisting of cardiomyopathy, myopathy, and intellectual disability. Additional clinical manifestations include retinal disease,[3–5] hepatic disease,[6–7] and pulmonary disease.[8] Furthermore, studies in LAMP-2 knockout mice have shown that many organs are affected, including the kidneys, pancreas, small intestine, thymus, and spleen.[9] At present, treatment interventions for Danon disease are mainly limited to the prevention of sudden death and heart failure through cardioverter defibrillator (ICD) implantation and heart transplantation. This report is of a case of a 19-year-old man with Danon disease who underwent cardiac ablation procedures and cardiac resynchronization therapy. The LAMP2 mutation in this patient had not been previously reported, making it a rare phenotype.
2. Case report

A 19-year-old man, previously in good health, was hospitalized for intermittent heart palpitations. There was no family history of cardiomyopathy, arrhythmia, or sudden cardiac death. His sister had died of cirrhosis at age 12 years, but the exact cause of this cirrhosis was unknown. A physical examination showed that this patient was hemodynamically stable. An electrocardiogram (ECG) showed Wolff-Parkinson-White (WPW) syndrome with paroxysmal wide QRS tachycardia (Fig. 1A and B). An echocardiogram revealed left ventricular wall thickening, suspected hypertrophic non-obstructive cardiomyopathy, and myocardial amyloidosis with an initial septal thickness of 17 mm and a left ventricular wall thickness of 13 mm (Fig. 2A and B).

Pertinent laboratory test results (Table 1) included elevated serum concentrations of myo-inositol (667.5 ng/mL, normal < 107 ng/mL), cardiac troponin (CTnI; 0.187 ng/mL, normal < 0.05 ng/mL), creatine kinase-MB (5.40 ng/mL, normal < 4.3 ng/mL), aspartate aminotransferase (262.5 U/L, normal 15–40 U/L), and alanine aminotransferase (136.1 U/L, normal 9.0–50 U/L). During the process of radiofrequency ablation, the patient repeatedly showed atrioventricular block (AVB; Fig. 1C). However, after 3 radiofrequency ablation procedures, his WPW disappeared, but he continued to show second degree AVB (Fig. 1D).

Two years after radiofrequency ablation, the patient was again hospitalized for palpitations and dizziness. On physical examination, his apical beat was diffuse, his cardiac boundaries were enlarged to the left, and systolic murmurs were heard in the auscultation areas of his bicuspid and tricuspid valves. ECG indicated atrial flutter, WPW, and third-degree AVB (Fig. 1E and F). An echocardiogram showed that myocardial densification was incomplete, his left atrium and ventricle were enlarged, his left ventricular beat was diffusely weakened, and his systolic function was reduced. His mitral and tricuspid valves showed regurgitation and thickening of the interventricular septum, with a left ventricular diastolic diameter of 68 mm, a left ventricular wall thickness of 9 mm, a septal thickness of 12 mm, and an ejection fraction of 46% (Fig. 2C and D). Furthermore, cardiovascular magnetic resonance imaging (CMRI) indicated suspected amyloidosis of the cardiac muscle (Fig. 3). His laboratory test results had deteriorated since his previous admission, with his serum myo-inositol, creatine kinase-MB, aspartate aminotransferase, and alanine aminotransferase concentrations being higher than before, and his brain natriuretic peptide concentration being elevated (824.0 pg/mL, normal < 100 pg/mL) (Table 1). Amyloid cardiomyopathy was excluded by performing relevant laboratory tests and pathological diagnosis of the adipose tissue attached to the walls. Hyperplasia was observed in the fibrous tissue of the dermis, along with widening of the subcutaneous fat lobule space and positive Congo red staining (Fig. 4). These results did not support a diagnosis of amyloid cardiomyopathy (Table 2), and the transthyretin (TTR) gene was negative. A cardiac resynchronization therapy pacemaker was implanted to relieve the patient’s clinical symptoms. Fifteen days later, he returned to our hospital because of a skin infection at the pacemaker implantation site and was given a permanent replacement pacemaker.

One month later, the patient was again hospitalized at our institution because of repeated aggravation of heart failure and the appearance of symptoms of restlessness and confusion.
abnormality was found on computed tomography of the head. No improvement was observed after symptomatic treatment, and he died of cardiac arrest.

Subsequent genetic testing revealed that this patient was hemizygous for a previously unreported deletion mutation (p.Gly221Ilefs*19) in the LAMP2 gene, confirming the diagnosis of Danon disease (Fig. 5). A myocardial biopsy was not performed.

3. Discussion

Danon disease is an X-linked dominant genetic disease. Its primary genetic defect, a mutation in the LAMP-2 gene, disrupts autophagy, leading to impaired fusion of lysosomes to autophagosomes, and the biogenesis of lysosomes. However, the exact function of the LAMP2 and the mechanisms by which LAMP2 deficiency causes Danon disease are not well understood. Because Danon disease has an X-linked mode of inheritance, clinical symptoms appear earlier and are more severe in male patients. Because men transmit this trait to all their daughters, more girls than boys should have Danon disease. However, because this disease is less severe in females, many go undiagnosed. The epidemiological characteristics of Danon disease are currently unknown, but it can affect any race or ethnic group. Although the clinical manifestations of Danon disease are a classic triad of cardiomyopathy, skeletal myopathy, and intellectual disability, its early clinical features are not obvious in most patients. Danon disease usually manifests initially as cardiac murmurs, chest pain, palpitations and/or fatigue, all of which are easy to ignore. There are no currently established guidelines for the diagnosis or management of patients with Danon disease. Cardioverter implantation is necessary for patients with moderate to severe cardiomyopathy, symptomatic arrhythmia, and Danon disease with a family history of sudden early death. Radiofrequency ablation can provide temporary treatment for patients with arrhythmia, but it may not be effective because of diffuse myocardial fibers and the rapid progress of fibrosis. Heart transplantation should be considered early, especially in young men with rapidly progressing cardiomyopathy and a family history of sudden death. The prognosis for patients with Danon disease mainly depends on the severity of cardiomyopathy, with the need for cardiac transplantation being inevitable for most males in their second and third decades of life.

The delayed diagnosis of this patient was due to our insufficient understanding of this rare disease. Apart from the classic triad, most patients with Danon disease are atypical and require careful screening. Arrhythmias are common in patients with Danon disease, affecting 86% to 100% of men.

Ventricular pre-excitation is the most common ECG abnormality in patients with Danon disease, with an incidence of 68.2% in men and 26.7% in women. Because of the presence of accessory pathways, the annulus fibrosus in most patients cannot completely separate the atria and ventricles, leading to ventricular pre-excitation. Danon disease associated with paroxysmal supraventricular tachycardia is also known as WPW syndrome. However, ventricular pre-excitation in

### Table 1

| Blood test    | First admission | 2 yr later | Normal   |
|---------------|----------------|-----------|----------|
| MYO (ng/mL)   | 687.5          | >500      | 0–107    |
| CK (U/L)      | 0.187          | <0.05     | 0–0.05   |
| CK-MB (ng/mL) | 5.40           | 4.60      | 0–4.3    |
| D-D (ng/mL)   | 624            | 100–600   |          |
| BNP (ng/mL)   | 824.0          | 0–100     |          |
| AST (U/L)     | 262.5          | 361.7     | 15.0–40.0|
| ALT (U/L)     | 136.1          | 138.5     | 9.0–50.0 |

ALT = alanine transaminase, AST = aspartate transaminase, BNP = B-type natriuretic peptide, CK-MB = creatine kinase isoenzymes, cTnI = cardiac troponin I, D-D = dimer, MYO = myo-inositol.
some patients with Danon disease may be due to fasciculoven-
tricular rather than atrioventricular pathways. The patient
described in this report was admitted to the hospital with
ventricular tachycardia. During radiofrequency ablation, AVB
repeatedly appeared, indicating that the atrioventricular node
was functioning poorly. Accelerated disease progression in this
patient may have been caused by our cutoff of accessory
pathways based on his symptoms. Furthermore, radiofrequency
ablation in patients with Danon disease is not always successful
due to diffuse and rapid fibrosis of the myocardium.

Although ICDs are implanted toward the end-stage of the
disease, sudden cardiac death may not be avoided. In 1 study
of 7 patients who received an ICD, implantation ultimately failed
to terminate fatal ventricular tachyarrhythmias in 5 patients. Therefore, early heart transplantation is necessary for patients
with a high risk of sudden death.

In women, Danon disease usually manifests as isolated heart
disease, whereas men may manifest damage to multiple
systems. Because the clinical manifestations of this disease
are non-specific, an early diagnosis may be difficult. Our patient
initially presented with cognitive and mental disorders, but a
computed tomography examination of his head showed no
organic disease. We also thought that this patient’s mental
symptoms were associated with the pain of this disease, without
considering the mental abnormalities accompanying Danon
disease. About 70% to 100% of affected men have learning
disabilities and cognitive deficits, although they can learn to read,
hold a job, build relationships, and usually live independently.
In a study of 13 patients with Danon disease, nine had normal
intelligence scores and only 1 had an intellectual disability.
However, 69% of patients with this condition have been reported
to meet the diagnostic criteria for at least 1 mental disorder,
usually emotional and anxiety disorders.\textsuperscript{[26]} Other mental disorders can include measurement disorders, language disorders, attention deficits, and behavioral problems.\textsuperscript{[9]} Although studies have reported cognitive problems,\textsuperscript{[14,27]} these problems have not been described in detail.

This patient experienced symptoms of fatigue during the later stages of disease. Abnormally elevated creatine kinase concentration and skin rupture at the site of the ICD suggest muscle damage. The liver may be a component of skeletal myopathy, leading to an increase in liver enzymes.\textsuperscript{[15]} About 80% to 100% of patients with Danon disease have skeletal muscle disease,\textsuperscript{[25,28]} with the common clinical manifestations being asthenia\textsuperscript{[29]} and exercise intolerance.\textsuperscript{[28]} Severe skeletal muscle weakness and respiratory failure have also been observed in patients with Danon disease\textsuperscript{[30]} with men having levels of creatine kinase 3 to 35 times higher than normal.

In addition, we neglected the results of relevant auxiliary examinations. Color Doppler echocardiography in our patient showed that the left ventricular wall was thickened. As Danon disease progresses, the left atrium and left ventricle become enlarged, gradually reducing systolic capacity. Cardiomyopathy has been reported as progressive in patients with Danon disease, with the typical manifestation being hypertrophic cardiomyopathy (HCM). Moreover, ejection fraction and lumen diameter often remain unchanged during the early stages of disease. After age 26 years, 11% to 12% of men with this condition develop dilated cardiomyopathy.\textsuperscript{[9]} In addition, the types of cardiomyopathy differ by sex, with most men having HCM, and similar percentages of women having HCM and dilated cardiomyopathy.\textsuperscript{[14,18–20]} In a study of 197 patients with left ventricular hypertrophy of unknown cause, ten patients were confirmed to have electrocardiographic pre-excitation by next generation sequencing, with 3 having different mutations of the LAMP2 gene.\textsuperscript{[15]} These findings suggest that Danon disease should be highly suspected in patients with left ventricular hypertrophy and ventricular pre-excitation, 1 of the clinical manifestations we neglected.

Cardiac CMRI may have potential clinical utility and provide valuable morphological and structural information in patients with Danon disease. The late gadolinium enhancement (LGE) observed in Danon disease does not seem to be typical in patients with other causes of left ventricular hypertrophy. For example,

### Table 2

| Factors tested                              | Results | Normal   | Factors tested                              | Results | Normal   |
|---------------------------------------------|---------|----------|---------------------------------------------|---------|----------|
| 24 hr urine lambda light chain (mg/24 h)    | 3.78    | <7.80    | Serum free λ chain (mg/L)                   | 26.00   | 8.3–27.00|
| 24 hr urine kappa light chain (mg/24 h)     | 6.97    | <14.20   | Serum free κ chain (mg/L)                   | 23.10   | 6.7–22.4 |
| Immunoglobulin κ light-chain                | -       | -        | Albumin (%)                                 | 52.6    | 60.0–71.0|
| Immunoglobulin λ light-chain                | -       | -        | α1 globulin (%)                             | 3.0     | 3.0–4.0  |
| IgA                                         | -       | -        | α2 globulin (%)                             | 8.4     | 6.0–10.0 |
| IgG                                         | -       | -        | β globulin (%)                              | 11.3    | 7.0–11.0 |
| IgM                                         | -       | -        | γ globulin (%)                              | 24.7    | 9.0–18.0 |
| Total protein (g/L)                         | 69.5    | 65.0–85.0| 24 hr urine volume (L/24 h)                 | 2.400   |          |

Ig = immunoglobulin.
LGE in patients with amyloidosis usually manifests as global transmural or subendocardial LGE with a characteristic “zebra” pattern. In patients with sarcoidosis, LGE has been found to involve the basal and/or mid-ventricular septum, whereas, in patients with Anderson-Fabry disease, LGE frequently involves the inferolateral segments with intramyocardial distribution.[2,12] CMRI found that all patients who had been diagnosed with Danon disease and the HCM phenotype had LGE that included the anterior, posterior, or lateral wall, with a subendocardial, intramyocardial, or transmural distribution. Only 1 patient (20%) showed involvement of the interventricular septum.[21] CMRI in the present patient showed LGE involving the diffuse subendocardial and inter mural walls of the left ventricular free wall and the muscular wall of the right ventricle wall.

Our patient was found to have rare ventricular septa, different from the involved sites of other patients with the HCM phenotypes. The range of involvement in our patient was uncommon pathologically. These findings indicate that the LAMP2 gene should be analyzed as soon as possible in patients with HCM phenotypes and in LGE patients with other pathologically abnormal distributions.

In addition to the increase in brain natriuretic peptide, cTnI was also increased in our patient. Increased cTnI has been observed during the acute stage of cardiac symptoms, especially in cases of rapid death. Recent reports indicate that an increase in cTnI has predictive value, although large-scale clinical studies are required to confirm this possibility.[23]

What has always confused us is the results of both color Doppler echocardiography and CMRI suggested the possibility of cardiac amyloidosis, as the latter is caused by abnormal protein (amyloid) deposition in cardiac tissue.[31] The monoclonal immunoglobulin light-chain (AL; or primary systemic) type and (TR; formerly smIle) type are most common in cardiac amyloidosis.[32] Because AL amyloidosis is mainly related to plasma cell disease, the number of relevant laboratory tests was increased, suggesting that the results in this patient were not consistent with AL amyloidosis. Moreover, this patient was negative on the TTR gene test, excluding the likelihood of TTR amyloidosis. When laboratory results are unclear, histological examination remains the diagnostic standard for amyloid cardiomyopathy. In addition to Congo red staining being positive, polarized light microscopy of amyloid fibrils stained with Congo red yielded characteristic apple green birefringence and intense yellow-green fluorescence with thioflavim.[31] Unfortunately, we only performed Congo red staining, and the abdominal fat biopsy of this patient was positive. In addition to amyloid, other positively stained tissue elements include elastin, collagen, and eosinophils.[33] However, the reason for the positive Congo red staining in this patient is uncertain.

Danon disease is a rare X-linked dominant disease, caused by mutations in the LAMP2 gene located at Xq24-q25.[10] At least 110 different mutations in the LAMP2 gene have been detected, with the c.926G>T-A mutation (causing exon 7 skipping) being the most common.[7] The p.Gly221Ilefs*19 mutation in the present patient had not been previously reported, suggesting it is a rare phenotype. Although this gene was from the patient’s mother, and women are more likely to inherit Danon disease than men, the cause of his younger sister’s death remains unclear. Because clinical symptoms are less severe in women with Danon disease, the disease is more insidious and cannot be diagnosed without gene diagnosis. Therefore, early molecular diagnosis and genetic counseling are very important for diagnosis and treatment.

The patient described in this study lived 2 years from the onset of symptoms to the onset of heart failure, and died of cardiogenic death in the third year. Patients with Danon disease often progress from being asymptomatic or having imperceptible symptoms to rapid deterioration and heart failure.[13] Greater understanding of Danon disease may help with its early diagnosis and active treatment, especially if early heart transplantation can prolong survival.

Author contributions
Data curation: Hang Ren.
Software: Hang Ren.
Supervision: Shan shan Zhou.
Writing – original draft: Ying Zhang.
Writing – review & editing: Ying Zhang, Shan shan Zhou.

References
[1] Kuroda K, Seguchi O, Matama H, et al. Left ventricular assist device implantation in an adult male with Danon disease. J Cardiol Cases 2019;20:106–9.
[2] Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med 2011;13:563–8.
[3] Thompson DA, Constable PA, Liasis A, et al. The physiology of the retinal pigment epithelium in danon disease. Retina (Philadelphia, Pa) 2016;36:629–38.
[4] Prall FR, Drack A, Taylor M, et al. Ophthalmic manifestations of Danon disease. Ophthalmology 2006;113:1010–3.
[5] Schorderet DF, Cotter S, Lobrinus JA, et al. Retinopathy in Danon disease. Arch Ophthalmol 2007;125:231–6.
[6] Sugie K, Yamamoto A, Murayama K, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 2002;58:1773–8.
[7] Cenacchi G, Papa V, Pegoraro V, et al. Review: Danon disease: review of natural history and recent advances. Neuropathol Appl Neurobiol 2019;46:303–22.
[8] Konrad T, Sonnenschein S, Schmidt FP, et al. Cardiac arrhythmias in patients with Danon disease. Europace 2017;19:1204–10.
[9] D’Souza RS, Levandowski C, Slavov D, et al. Danon disease: clinical features, evaluation, and management. Circ Heart Fail 2014;7:943–9.
[10] Dougu N, Joho S, Shan L, et al. Novel LAMP-2 mutation in a family with Danon disease presenting with hypertrophic cardiomyopathy. Circ J 2009;73:376–80.
[11] Marino M, Musumeci O, Paleologo G, et al. Ischemic stroke due to hyperperfusion in a patient with a previously unrecognized Danon disease. Neuromusc Disord 2016;26:890–4.
[12] D’Souza RS, Mestrioni L, Taylor MRG. Danon disease for the cardiologist: case report and review of the literature. J Community Hosp Intern Med Perspect 2017;7:107–14.
[13] Lobrinus JA, Schorderet DF, Payot M, et al. Morphological, clinical and genetic aspects in a family with a novel LAMP-2 gene mutation (Danon disease). Neuromuscul Disord 2005;15:293–8.
[14] Liu Y, Wang F, Chen X, et al. Fasciculoventricular pathways responsible for ventricular preexcitation in patients with danon disease. Circ Arrhythm Electrophysiol 2018;11:e006704.
[15] Liu Y, Chen X, Wang F, et al. Prevalence and clinical characteristics of Danon disease among patients with left ventricular hypertrophy and concomitant electrocardiographic preexcitation. Mol Genet Genomic Med 2019;7:e638.
[16] Jhaveri S, Herber J, Zahka K, et al. Arrhythmias and fasciculoventricular pathways in patients with Danon disease: a single center experience. J Cardiovasc Electrophysiol 2019;30:1592–8.
[17] Cheng Z, Cui Q, Tian Z, et al. Danon disease as a cause of concentric left ventricular hypertrophy in patients who underwent endomyocardial biopsy. Eur Heart J 2012;33:649–56.
[18] Fanin M, Nascimbene AC, Fulizio L, et al. Generalized lysosome-associated membrane protein-2 defect explains multisystem clinical involvement and allows leukocyte diagnostic screening in Danon disease. Am J Pathol 2006;168:1309–20.
[19] Cheng Z, Fang Q. Danon disease: focusing on heart. J Hum Genet 2012;57:407–10.
[20] Endo Y, Furuta A, Nishino I. Danon disease: a phenotypic expression of LAMP-2 deficiency. Acta Neuropathol 2015;129:391–8.
[21] Nucifora G, Miani D, Piccoli G, et al. Cardiac magnetic resonance imaging in Danon disease. Cardiology 2012;121:27–30.
[22] Piotrowska-Kownacka D, Kownacki L, Koch M, et al. Cardiovascular magnetic resonance findings in a case of Danon disease. J Cardiovasc Magn Reson 2009;11:12.
[23] Roos JCP, Daniels MJ, Morris E, et al. Heterogeneity in a large pedigree with Danon disease: Implications for pathogenesis and management. Mol Genet Metab 2018;123:177–83.
[24] Brambatti M, Caspi O, Maolo A, et al. Danon disease: gender differences in presentation and outcomes. Int J Cardiol 2019;286:92–8.
[25] Sugie K, Komaki H, Eura N, et al. A nationwide survey on danon disease in Japan. Int J Mol Sci 2018;19:.
[26] Yardeni M, Weissman O, Mandel H, et al. Psychiatric and cognitive characteristics of individuals with Danon disease (LAMP2 gene mutation). Am J Med Genet A 2017;173:2461–6.
[27] Rowland TJ, Sweet ME, Mestroni L, et al. Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J Cell Sci 2016;129:2133–43.
[28] López-Sainz Á, Salazar-Mendiguchía J, García-Álvarez A, et al. Clinical findings and prognosis of danon disease. An analysis of the spanish multicenter danon registry. Rev Esp Cardiol (Engl Ed) 2019;72:479–86.
[29] van der Kooi AJ, van Langen IM, Aronica E, et al. Extension of the clinical spectrum of Danon disease. Neurology 2008;70:1358–9.
[30] Bui YK, Renella P, Martinez-Agosto JA, et al. Danon disease with typical early-onset cardiomyopathy in a male: focus on a novel LAMP-2 mutation. Pediatr Transplant 2008;12:246–50.
[31] Bhogal S, Ladia V, Sitwala P, et al. Cardiac amyloidosis: an updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol 2018;43:10–34.
[32] Kotecha T, Martinez-Naharro A, Treibel TA, et al. Myocardial edema and prognosis in amyloidosis. J Am Coll Cardiol 2018;71:2919–31.
[33] Yakupova EI, Bobyleva LG, Vikhlyantsev IM, et al. Congo Red and amyloids: history and relationship. Biosci Rep 2019;39: